1,000+ Opportunities
Find the right grant
Search federal, foundation, and corporate grants with AI — or browse by agency, topic, and state.
This listing may be outdated. Verify details at the official source before applying.
Find similar grantsResearch on the Neuro-Immune Axis in the context of HIV and Substance Use (R01 Clinical Trial Not Allowed) is sponsored by National Institute on Drug Abuse (NIDA). This opportunity supports mission-aligned projects and measurable outcomes.
Get a weekly digest of new grants like this
A free weekly digest of new foundation and federal funding opportunities as they're added to Granted. Unsubscribe anytime.
Or search similar grants →Extracted from the official opportunity page/RFP to help you evaluate fit faster.
Research on the Neuro-Immune Axis in the context of HIV and Substance Use (R01, R21 Clinical Trial Not Allowed) | Research Funding National Institutes of Health Research on the Neuro-Immune Axis in the context of HIV and Substance Use (R01, R21 Clinical Trial Not Allowed) The purpose of this notice of funding opportunity (NOFO) is to support research towards identifying and characterizing neuroimmune networks, communication pathways, and targets that reside within neuroimmune axes, in the context of HIV and substance use.
This NOFO will also support research on the discovery of novel modulatory probes/tools that can advance our knowledge of the regulatory mechanisms by which neuroimmune interactions contribute to HIV and substance use disorder comorbidity. Applications testing a fully conceptualized premise founded with adequate preliminary data are appropriate for this NOFO.
Exploratory research projects should consider applying to the companion R21 announcement RFA-DA-25-005. Letter of Intent Due Date(s): October 13, 2024 AIDS Application Due Date: November 13, 2024 RFA-DA-25-004 Expiration Date November 14, 2024 Medical - Clinical Science
According to the current listing, eligibility includes: All organizations administering an eligible parent award may apply for a supplement under this NOFO. Universities are generally eligible for R01 grants. Confirm the full requirements in the official notice before applying.
The current listing shows NIDA intends to commit $2M in FY 2025 to fund up to six awards in response to RFA-DA-25-004 and the companion NOFO RFA-DA-25-005. Verify award ceilings, matching requirements, and allowable costs in the official notice.
Research on the Neuro-Immune Axis in the context of HIV and Substance Use (R01 Clinical Trial Not Allowed) is funded by National Institute on Drug Abuse (NIDA). Verify program details on the funder's official page before applying.
Start from the official opportunity page linked in this listing — it carries the sponsor's submission instructions.
Past winners and funding trends for this program
The HEAL Initiative's Studies to Enable Analgesic Discovery award (RFA-NS-25-023) puts federal money exactly where private capital won't go — the assay-building, screening, and hit-characterization stage of non-opioid pain therapeutics. It's a phased R61/R33, up to $350,000 in direct costs per year, with the next application deadline September 17, 2026. Here is how the two-phase structure works, who's eligible, and how to build a proposal that survives the R61-to-R33 milestone gate.
Read articleARPA-H's FASTPASS program targets a public-health blind spot: substandard and contaminated drugs that are only caught after patients are exposed. It funds through-package chemical sensing (TA1 SAMPLE) and the analytics to act on it (TA2 DETECT). The solicitation posts to SAM.gov in mid-August 2026, with a virtual Proposer Workshop on August 24 and registration closing August 20. Here is what FASTPASS funds, why the timing matters, and how to position a cross-disciplinary team.
Read articleARPA-H PROSPR program funds seven research teams testing rapamycin, semaglutide, and novel compounds to extend healthspan. A deep analysis of the science, the money, and what it means for the field.
Read article